OraSure Technologies (OSUR) DCF: History & Chart

OraSure Technologies, Inc.(OSUR)

Medical - Instruments & Supplies · Bethlehem, PA

$3.77-0.34 (-8.27%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About OraSure Technologies, Inc.

OraSure Technologies, Inc. and its affiliates are a global leader in the development, production, and commercialization of advanced oral fluid diagnostic solutions and specialized specimen collection tools, serving markets across the United States, Europe, and other international regions. The company operates through two primary divisions: Diagnostics and Molecular Solutions. Its diverse Diagnostics portfolio features a range of crucial offerings, such as the InteliSwab rapid tests for COVID-19 (including professional and prescription versions). It also provides several OraQuick rapid tests, encompassing solutions for HIV (Rapid, In-Home, and Self-Test versions), Hepatitis C (HCV rapid antibody), and Ebola (rapid antigen). Further diagnostic tools include the OraSure oral fluid collection device, utilized for HIV-1 antibody screening and confirmation; the Intercept drug testing systems; various immunoassay tests and reagents; and the Q.E.D. saliva alcohol test. Within its Molecular Solutions segment, OraSure offers an array of genomic products, notably under the Oragene and ORAcollect brand names, alongside specialized microbiome collection solutions and comprehensive GenoFIND genomics laboratory services. The company also supplies collection devices like ORAcollect, RNA, OMNIgene, and RAL, specifically designed for COVID-19 molecular testing. Another key offering is the Colli-Pee device, engineered for the precise volumetric collection of first-void urine. Furthermore, OraSure produces and distributes advanced kits for the collection, stabilization, transportation, and storage of genetic material samples, critical for molecular testing in diverse fields such as academic research, commercial applications (including ancestry, disease risk management, lifestyle analysis), and animal testing. Complementing these, it also provides various other diagnostic tools, including immunoassays and in vitro diagnostic tests. OraSure's sophisticated products and services are distributed to a wide array of clients, including clinical laboratories, hospitals, clinics, various community and public health organizations, wholesale distributors, governmental bodies, medical practices, and a broad spectrum of commercial and industrial entities. Established in 2000, OraSure Technologies, Inc. maintains its corporate headquarters in Bethlehem, Pennsylvania.

Bethlehem, PA

500 employees

www.orasure.com

Healthcare / Medical - Instruments & Supplies

Sector: Healthcare
Industry: Medical - Instruments & Supplies
CEO: Carrie Eglinton Manner

View full financials

OraSure Technologies, Inc. (OSUR) DCF Valuation

Why we don't show a single “fair value” for OSUR

A trailing-FCF DCF can't fairly anchor OraSure Technologies, Inc. right now — free cash flow has been negative in recent years. For a company in this position, trailing free cash flow understates what the business actually earns for owners, so any “fair value” built on it would be misleadingly low. Off today's cash-flow base, no plausible growth rate bridges to the current price — the market is valuing normalized future cash flows, not the depressed base. The model scenarios below are shown for reference only.

Scenario	FCF growth (fading to 2.5%)	Discount	Value / share
Conservative	0.5%/yr	10.1%	$5.02
Base case	2.0%/yr	9.1%	$5.49
Optimistic	5.0%/yr	8.1%	$6.37
Third-party model estimate (FMP)	independent reference · retrieved Oct 6, 2026 · assumptions not provided		$0.44

The FMP figure is a third-party point estimate. Its cash-flow forecast, discount rate, terminal growth, and valuation date are not included in the stored response, so TGMCharts presents it only as a reference—not as an intrinsic-value conclusion or price target.

Price|PE Ratio|FCF Yield|All Metrics

Current Price

$3.77

Market-Implied Growth

N/A

Base-Case Model Value

$5.49

model output — not a price target

OSUR DCF Fair Value Calculator

Edit the assumptions to see how they change the estimated fair value. Opens seeded with TGM's data-driven base case for OSUR (growth from its own 5-year record, discount from its beta), so the sandbox starts where the scenarios above leave off. Illustrative model — not investment advice.

FCF Growth Rate2%/yr

Historical FCF CAGR: N/A

Discount Rate (WACC)9.1%

Terminal Growth2.5%

Projection Years10yr

Base inputs: FCF $11.8M · 0.07B shares · net cash $199.3M

Estimated Fair Value

$5.49

+45.7% vs $3.77

Current price$3.77

Third-party model estimate (FMP)$0.44

Sensitivity — fair value by discount rate × terminal growth

How the estimated fair value shifts with the discount rate (WACC) and terminal growth, holding your 2.0%/yr FCF growth and 10-year horizon fixed. Green = above today's $3.77; red = below. Your current case is outlined.

WACC ↓ / Terminal →	1.50%	2.00%	2.50%	3.00%	3.50%
7.1%	$6.06	$6.31	$6.62	$7.00	$7.49
8.1%	$5.58	$5.75	$5.96	$6.20	$6.50
9.1%	$5.22	$5.35	$5.49	$5.66	$5.86
10.1%	$4.95	$5.05	$5.15	$5.27	$5.41
11.1%	$4.74	$4.81	$4.89	$4.98	$5.08